DuPont de Nemours, Inc. Total Cost of Revenue decreased by 1.5% to $1.08B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.9%, from $1.07B to $1.08B. Over 3 years (FY 2021 to FY 2025), Total Cost of Revenue shows a downward trend with a -17.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.96B | $2.03B | $2.12B | $2.11B | $2.15B | $2.10B | $2.05B | $1.98B | $2.03B | $1.95B | $1.10B | $1.13B | $1.13B | $1.14B | $1.07B | $1.14B | $1.18B | $1.10B | $1.08B |
| QoQ Change | — | +3.7% | +4.3% | -0.4% | +1.8% | -2.5% | -2.2% | -3.2% | +2.4% | -3.7% | -43.8% | +3.0% | +0.3% | +0.2% | -5.9% | +6.9% | +3.1% | -7.1% | -1.5% |
| YoY Change | — | — | — | — | +9.7% | +3.1% | -3.4% | -6.0% | -5.5% | -6.7% | -44.6% | -44.3% | -42.0% | — | -2.6% | +1.1% | +4.0% | -3.6% | +0.9% |